To analyze the characteristics of retracted oncology papers from Chinese scholars and the reasons for retraction. Data on retracted oncology papers from Chinese scholars published from 2013 to 2022 were retrieved from the Retraction Watch database. The retraction number and annual distribution, article types, reasons for retraction, retraction time delay, publishers, and journal characteristics of the retracted papers were analyzed. A total of 2695 oncology papers from Chinese scholars published from 2013 to 2022 had been retracted. The majority of these papers were published from 2017 to 2020. In terms of article type, 2538 of the retracted papers were research articles, accounting for 94.17% of the total number of retracted papers. The main reasons for retraction were data, result, and image problems, duplicate publication, paper mills, author- and third-party-related reasons, plagiarism, false reviews, and method errors. The retraction time delay for the retracted papers ranged from 0 to 3582 days (median, 826 days). The retractions mainly occurred within the first 4 years after publication. A total of 77 publishers were involved in the retracted papers. In terms of journal distribution, 394 journals were involved in the retracted papers, of which 368 (93.40%) were included in the SCI database. There were 243 journals with an impact factor of <5 (66.03%). In the field of oncology, the annual distribution of retracted papers from Chinese scholars exhibited first an increasing and subsequently a decreasing trend, reaching a peak in 2019, indicating an improvement in the status of retraction after 2021. The main type of the retracted papers was research article, and the main reason for retraction was academic misconduct. The retractions were mainly concentrated in several major publishers and periodicals in Europe and the United States. Most of the journals had low-impact factors.
Read full abstract